Dallas, Texas--(Newsfile Corp. - April 1, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition exited FY25 with ZUNVEYL showing increasingly durable traction in long-term care, as 4Q25 net product revenue reached $2.5M and FY25 total revenue reached $10.2M, including $6.8M of ZUNVEYL sales. More importantly, demand indicators continued to inflect, with bottles dispensed rising 62% q/q to 4,941 with December alone reaching a record 1,859 bottle. Repeat ordering remained strong, supporting management's view that ZUNVEYL is moving beyond early trial use and becoming more embedded in facility treatment protocols.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- ZUNVEYL adoption is becoming durable. 4Q25 sales hit $2.5M, bottles dispensed rose 62% q/q to 4,941, and December reached 1,859.
- LTC traction is strengthening with repeat behavior. 729 ordering homes, 82% repeat orders, and 865 prescribers with 69% repeat writers support protocol adoption.
- ACOG is funded to keep scaling commercialization. Ended FY25 with $66.0M cash, runway into 2027, and expects continued sequential sales growth in 2026.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290861
Source: Reportable, Inc.